Literature DB >> 28204882

Comparison between vaginal and sublingual misoprostol 50 µg for cervical ripening prior to induction of labor: randomized clinical trial.

Andrés Conde1,2, Sebastián Ben3, Josefina Tarigo3, Santiago Artucio3, Virginia Varela3, Pamela Grimaldi3, Claudio Sosa3, Justo Alonso3.   

Abstract

OBJECTIVE: To compare the effectiveness and safety of sublingual versus vaginal misoprostol on improving the Bishop score after 6 h of administration.
METHODS: Randomized clinical trial which includes pregnant women in gestational ages from 32/0 to 41/6, with indication of induction of labor with misoprostol. Bishop score was assessed at the time of induction and 6 h after administration of 50 µg misoprostol. Analysis was made over difference in mean Bishop score of 2 points, using a standard deviation of 2, with 90% power, reaching a 95% confidence interval.
RESULTS: 102 patients were studied, 51 received sublingual misoprostol, and 51 received vaginal misoprostol. There was a statistically significant difference in cervical modifications in global terms regardless of the administration route at 6 h (P < 0.05). When analyzing each group, there was no significant difference for the mean and standard deviation for Bishop score for sublingual and vaginal route (P = 0.761). There was no significant difference in terms of mode of delivery, Apgar score, cord pH, nor in the presence of complications.
CONCLUSION: There is no statistically significant difference in terms of administration route for cervical ripening using misoprostol 50 µg, whether it was sublingual or vaginal. TRIAL REGISTRATION NUMBER: NCT02732522. Registry website: https://clinicaltrials.gov/ .

Entities:  

Keywords:  Cervical ripening; Misoprostol; Sublingual

Mesh:

Substances:

Year:  2017        PMID: 28204882     DOI: 10.1007/s00404-017-4297-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  1 in total

1.  Misoprostol administered sublingually at a dose of 12.5 μg versus vaginally at a dose of 25 μg for the induction of full-term labor: a randomized controlled trial.

Authors:  Daniele S M B Gattás; Melania M R de Amorim; Francisco E L Feitosa; José R da Silva-Junior; Lívia C G Ribeiro; Gustavo F A Souza; Alex S R Souza
Journal:  Reprod Health       Date:  2020-04-10       Impact factor: 3.223

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.